Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body.
Last updated on
About Nkarta
Founded
2015Estimated Revenue
$10M-$50MEmployees
51-250Funding / Mkt. Cap
$125MCategory
Industry
BiotechnologyLocation
City
South San FranciscoState
CaliforniaCountry
United StatesNkarta
Find your buyer within Nkarta